References
- Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiological features. J Clin Neurophysiol. 2001;18:128-147.
- Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101-119.
- Avecillas JF, Golish JA, Giannini C, Yataco JC. Restless legs syndrome: keys to recognition and treatment. Cleve Clin J Med. 2005;72:769-787.
- Chaudhuri KR, Forbes A, Grosset D, et al. Diagnosing restless legs syndrome (RLS) in primary care. Curr Med Res Opin. 2004;20:1785-1795.
- Data on file, Boehringer Ingelheim Pharmaceuticals, Inc.
- Desautels A, Turecki G, Montplaisir J, et al. Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity. Arch Neurol. 2005;62:591-596.
- Hening W, Walters AS, Allen RP, et al. Impact, diagnosis, and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med. 2004;5:237-246.
- MIRAPEX [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2007.
- National Institute of Neurological Disorders and Stroke. Restless legs syndrome fact sheet. Available at: http://www.ninds.nih.gov/disorders/restless_legs/
detail_restless_legs.htm?css=print. Accessed January 8, 2008. - The International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4:121-132.
- Trenkwalder C, Stiasny-Kolster K, Kupsch A, et al. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord. 2006;21:1404-1410.
- Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology. 2006;67:1034-1039.
Important Information about MIRAPEX: MIRAPEX is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
MIRAPEX may cause you to fall asleep without any warning, even while doing normal daily activities, such as driving. Before taking MIRAPEX, talk to your doctor if you drink alcohol or take other medications that make you drowsy as these can increase the chance that MIRAPEX will make you feel sleepy or fall asleep when you should be awake. When taking MIRAPEX, hallucinations (seeing, hearing, feeling, or tasting something that isn't there) may occur and you may sometimes feel dizzy, nauseated, faint or sweaty when you sit up or stand quickly. In clinical trials for RLS, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are nausea, headache, and tiredness. Talk to your doctor if you experience any of these symptoms.
There have been reports of impulse control disorders and compulsive behaviors in patients taking certain medicines, including MIRAPEX. If you or your family members notice that you are experiencing new or increased gambling urges, increased sexual urges or other intense urges, such as compulsive shopping or eating, while taking MIRAPEX, talk to your doctor.
This information is intended for U.S. residents only. Products discussed herein may have different labeling in different countries.
Please see full Prescribing Information, including patient information.
